Radiopharmaceutical excretion studies are a foundational component of preclinical ADME (Absorption, Distribution, Metabolism, and Excretion) evaluation, providing quantitative and kinetic data on how a radioactive candidate is cleared from the biological system. Recognizing that each RDC construct, whether peptide, antibody, or small molecule-based, presents a unique excretion and biodistribution profile, Alfa Cytology offers fully customized study designs. These services quantitatively track both the radioactive signature and the intact molecule/metabolite fate across urine, feces, and, where applicable, biliary routes, delivering the critical ADME data required for IND-enabling packages.
Radiopharmaceutical excretion studies are quantitative investigations designed to determine the primary routes and rates of elimination of a radiolabeled drug candidate from living systems. Unlike conventional small molecule excretion studies, these assessments must simultaneously account for the radioactive isotope's physical decay, the stability of the radiolabel in vivo, and the potential for metabolite redistribution. The study typically involves the administration of the test article at a pharmacologically relevant dose, followed by the systematic collection of excreta over multiple half-lives. Mass balance is rigorously calculated to account for the total administered radioactivity, differentiating between renal clearance (urine), hepatobiliary clearance (feces), and residual retention in tissues. For RDCs, this is further complicated by the fact that the linker-chelator-radionuclide complex may be processed differently than the targeting vector, necessitating a dual-analytical approach: counting total radioactivity and profiling the chemical forms present in excreta.
![Factors influencing the excretion kinetics of [177Lu]Lu‑PSMA‑617.](https://www.rdcthera.com/wp-content/themes/rdc-new/upload/4-2-7-radiopharmaceutical-excretion-study-services-1.jpg)
Fig.1 Correlation of [177Lu]Lu‑PSMA‑617 elimination rates with renal function markers and baseline tumor burden. (de Bakker, M., et al., 2023)
The excretion profile of an RDC is not merely a regulatory checkbox; it is a cornerstone of the drug's overall safety and feasibility evaluation. The unique nature of radiopharmaceuticals, where the therapeutic or diagnostic payload is intrinsically linked to a radioactive isotope, means that the elimination pathway directly impacts both target-tissue dosimetry and whole-body radiation burden.
Mitigating Off-Target Radiotoxicity
Pinpoints the exact organs of elimination (such as the kidneys for renal clearance or the large intestine for fecal clearance) to predict and prevent severe tissue damage like radiation nephropathy or GI tract toxicity.
Calculating Human Radiation Dosimetry
Supplies the foundational kinetic data required by regulatory bodies to extrapolate internal radiation dose estimates for human organs, establishing safe starting doses for First-in-Human (FIH) clinical trials.
Assessing In Vivo Linker Stability
Reveals whether the radioactive signal in the excreta represents the intact drug or cleaved free radionuclides, which serves as a direct indicator of the conjugate's structural integrity within the circulatory system.
Building on our extensive experience in radiochemistry, analytical method development, and preclinical pharmacology, Alfa Cytology provides a fully integrated suite of excretion study services. Our offering bridges the gap between basic radiometric counting and deep mechanistic understanding, providing you with a complete, decision-ready dataset that supports go/no-go decisions and regulatory submissions.
Alfa Cytology's specialized platform is fully equipped to characterize the elimination profile of diverse RDC modalities across a wide range of clinically relevant isotopes. The service covers the full spectrum of excretion analysis, from fundamental mass balance to detailed biotransformation characterization.
Quantitative determination of total radioactive dose recovery and the contribution of each elimination route, forming the quantitative backbone of the disposition profile.
Urinary and Fecal Clearance Mapping
Quantifying cumulative radioactivity recovered in urine and feces over sequential time intervals to delineate primary systemic elimination routes and derive corresponding clearance rates.
Hepatobiliary Clearance Evaluation
Performing specialized bile duct cannulation in appropriate preclinical models to directly quantify biliary excretion and identify potential enterohepatic recirculation patterns.
Terminal Tissue Retention Assessment
Determining the residual non‑excreted fraction retained in major organs (liver, kidneys, spleen, bone, and whole carcass) to support absorbed dose calculations and long‑term safety evaluation.
Total Material Accountability
Compiling comprehensive mass balance datasets with rigorous decay‑correction to ensure total administered radioactivity is accounted for within global regulatory recovery expectations.
Beyond simple counting, this pillar delivers the chemical and radiochemical resolution necessary to identify what molecular species are actually eliminated and in what proportions.
Matrix‑Specific Radioactivity Quantitation
Measuring total radioactivity counts in urine, feces, cage washes, and harvested tissues at each collection interval using calibrated detectors for accurate mass balance integration.
Excreta Radiochemical Stability Profiling
Resolving molecular species via radio‑chromatographic separation to distinguish intact RDC, free radionuclides, and intermediate catabolites or protein‑bound adducts in excreta.
In Vivo Linker Degradation Assessment
Correlating the temporal ratio of intact conjugate to free isotope in excreta to provide direct evidence of chelator stability and linker integrity under physiological conditions.
Flexible platform capabilities that accommodate the diverse physical and biological characteristics of current RDC pipelines, tailored to your targeting vector and development stage.
Multi-Isotope Platform Adaptability
Support for a comprehensive panel of clinically relevant radionuclides encompassing gamma-emitting diagnostic isotopes, beta-emitting therapeutic nuclides, and alpha-emitting payloads, with all study protocols systematically refined to accommodate each isotope's distinct half-life, emission type, energy spectrum, and shielding requirements, thereby ensuring accurate quantitation and safe execution across extended collection periods.
Cross-Species Translational Modeling
Utilization of standard rodent models (mouse and rat) for high-throughput screening, with feasibility for non-rodent species (rabbit, dog, or others) where regulatory bridging data are needed, and integration of specialized models such as bile-duct cannulated rodents for biliary clearance differentiation and tumor-xenograft systems for target-engagement assessment, with all data structured for direct allometric translation to human FIH projections.
A single oral dose of the 14C‑labeled test article was administered to male mice to evaluate its elimination kinetics and mass balance. Three animals were individually housed in metabolism cages, and urine and feces were collected at pre‑dose and over sequential intervals (0-6, 6-24, 24-48, and 48-72 hours) following dosing. Fecal excretion emerged as the predominant clearance pathway, accounting for approximately 96% of the recovered radioactivity, while urinary elimination represented less than 1% of the administered dose, indicating a minor role for renal clearance in this species. The candidate demonstrated rapid excretion kinetics in this model, with cumulative radioactivity recovery exceeding 90% within the first 48 hours post-dose, ultimately achieving a robust overall material recovery of 97% by the 72-hour termination checkpoint.
Fig.2 Time-course of total cumulative radioactivity recovery in mouse excreta following a single oral administration of the 14C-labeled candidate drug. Data are presented as mean ± SEM (n=3).
Successfully navigating the excretion and clearance profile of your RDC candidate is essential to defining its clinical viability. Whether you are advancing a novel small-molecule radioligand, a radiolabeled peptide, or an antibody-based RDC, Alfa Cytology's platform delivers the precise clearance data required to move your program safely into the clinic. Contact us to discuss your specific program needs and explore how our integrated approach can accelerate your RDC development timeline.
Reference
For research use only. Not intended for any clinical use.
Alfa Cytology, a provider of RDC preclinical services, specializes in RDC design, conjugation, and analysis. Supported by a rich library of radionuclides, chelators, and linkers, we excel in targeting molecule design. We offer customized RDC services tailored to diverse requirements-your demand is our mission.
Copyright © 2026 Alfa Cytology. All rights reserved.